FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia - Seite 4

Contacts Sanofi:

Media Relations Jack Cox Tel: [phone] Mobile: [phone] [e-mail]   Global Communications, PCSK9 Development & Launch Unit Elizabeth Baxter                                               Tel: [phone] Mobile: [phone]          [e-mail]

Investor Relations Sébastien Martel Tel: [phone] [e-mail]

Contacts Regeneron:

Media Relations                                               Arleen Goldenberg Tel: [phone] Mobile: [phone] [e-mail]

Investor Relations                                            Manisha Narasimhan Tel: [phone] [e-mail]

PDF Version of Press Release

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#1927451